Evidence map›Paper›PMID 24983280›Full record

Trial reportNeurosciences (Riyadh, Saudi Arabia)2014

Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial.

Nazanin Razazian, Maryam Baziyar, Nasrin Moradian, Daryoush Afshari, Arash Bostani, Marziyeh Mahmoodi

Registry-linked trialOpen access · greenAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC
In one paragraph

Trial report in Neurosciences (Riyadh, Saudi Arabia), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04246619 (Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04246619 phase4terminatednot on this mapstarted 2019, after this paper: background citation

Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)

TypeinterventionalSponsorKRKARan2019 to 2021Enrolled254ConditionsPainful Diabetic Peripheral NeuropathyArmsPregabalin, Duloxetine
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pregabalin for neuropathic pain in adults.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Chemotherapy-Induced Peripheral Neuropathy.Handbook of experimental pharmacology · 2023
    Article
  14. Article
  15. Current Strategies for the Management of Painful Diabetic Neuropathy.Journal of diabetes science and technology · 2022
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Psychotropic Drugs for the Management of Chronic Pain and Itch.Pharmaceuticals (Basel, Switzerland) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nazanin RazazianDepartment of Neurology, Imam Reza Hospital, College of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Maryam Baziyar
Nasrin Moradian
Daryoush Afshari
Arash Bostani
Marziyeh Mahmoodi
Kermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of carbamazepine, pregabalin, and venlafaxine in patients with painful diabetic neuropathy (PDN).

methodsOur study was performed as a randomized, double-blind, parallel-group clinical trial between December 2012 and December 2013 at Kermanshah University of Medical Sciences, Kermanshah, Iran. Two hundred and fifty-seven patients with clinically definite PDN were randomized to receive, carbamazepine, venlafaxine, or pregabalin. The primary outcome was subjective pain as assessed by the visual analogue scale (VAS). Secondary outcomes consisted of sleep, mood, and work interference assessments, and a percentage of patients achieving at least 50% reduction in pain intensity.

resultsMeans of VAS scores for carbamazepine, pregabalin, and venlafaxine treatment groups at the baseline (74.5, 82.3, and 74.5) and endpoint (39.6, 33.4, and 46.6) revealed significant reduction, although pregabalin was more efficacious than carbamazepine, and venlafaxine. Improvements in means scores of sleep, mood, and work interferences were identified in all treatment groups.

conclusionThis study showed the efficacy of venlafaxine, pregabalin, and carbamazepine in pain reduction in patients with diabetic neuropathy, although pregabalin was shown to be superior to carbamazepine, and venlafaxine in relieving pain, no significant superiority was shown between carbamazepine, and venlafaxine.

Indexed as

AdultAffectAgedAnalgesicsAnalgesics, Non-NarcoticCarbamazepineCyclohexanolsDiabetic NeuropathiesDouble-Blind MethodFemaleFollow-Up Studiesgamma-Aminobutyric AcidHumansMaleMiddle AgedPain MeasurementAnalgesicsAnalgesics, Non-NarcoticCarbamazepineCyclohexanolsgamma-Aminobutyric AcidPregabalinSelective Serotonin Reuptake InhibitorsVenlafaxine Hydrochloride

Identifiers

PMID24983280
PMCPMC4727652
OpenAlexW125400563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.